THE
FOLLOWING ANNOUNCEMENT IS BEING MADE PURSUANT TO THE REQUIREMENTS
OF RULE 19.6(C) OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE
"CODE"), WHICH, INTER ALIA, REQUIRES A PARTY TO AN OFFER TO MAKE AN
ANNOUNCEMENT AT THE END OF A PERIOD OF 12 MONTHS FROM THE DATE ON
WHICH THE OFFER PERIOD ENDED CONFIRMING WHETHER IT HAS TAKEN, OR
NOT TAKEN, THE COURSE OF ACTION SET OUT IN ITS STATED
INTENTIONS
FOR
IMMEDIATE RELEASE
20 September
2024
Novacyt
S.A.
("Novacyt", the "Company" or
the "Group")
Rule 19.6(c) confirmation in
respect of post-offer intention statements made in relation to
Yourgene Health plc ("Yourgene")
Novacyt announces that, further to the
completion of its recommended cash offer for the entire issued and
to be issued share capital of Yourgene, which was implemented by
way of a scheme of arrangement under Part 26 of the Companies Act
2006 and which became effective on 8 September 2023, it has duly
confirmed in writing to The Panel on Takeovers and Mergers in
accordance with the requirements of Rule 19.6(c) of the Code that
Novacyt has complied with their respective post-offer intention
statements made pursuant to Rules 2.7(c)(viii) and 24.2 of the
Code, as detailed in its announcement of 3 July 2023 and scheme
document published on 27 July 2023.
Contacts
|
Novacyt SA
|
https://novacyt.com/investors
|
|
Lyn Rees, Chief Executive
Officer
|
Via Walbrook
PR
|
|
Steve Gibson, Chief Financial
Officer
|
|
|
SP
Angel Corporate Finance LLP (Nominated Adviser and
Broker)
|
+44 (0)20
3470 0470
|
|
Matthew Johnson / Charlie Bouverat
(Corporate Finance)
Vadim Alexandre / Rob Rees
(Corporate Broking)
|
|
|
|
|
|
Deutsche Numis (Joint
Broker)
|
+44 (0)20
7260 1000
|
|
Freddie Barnfield / Duncan Monteith
/ Michael Palser
|
|
|
|
|
|
Allegra Finance (French Listing Sponsor)
Rémi Durgetto / Yannick
Petit
|
+33 (1) 42 22 10 10
r.durgetto@allegrafinance.com
/
y.petit@allegrafinance.com
|
|
|
|
|
Walbrook PR
(Financial PR & IR)
Stephanie Cuthbert / Paul McManus
/
Phillip Marriage / Alice
Woodings
|
+44 (0)20
7933 8780 or novacyt@walbrookpr.com
+44
(0)7796 794 663 / +44 (0)7980 541 893
+44
(0)7867 984 082 / +44 (0)7407 804 654
|
|
|
|
|
| |
About Novacyt Group (www.novacyt.com)
Novacyt is an
international molecular diagnostics company providing a broad
portfolio of integrated technologies and services, primarily
focused on the delivery of genomic medicine. The Company
develops, manufactures, and commercialises
a range of molecular assays and instrumentation to deliver
workflows and services that enable seamless end-to-end solutions
from sample to result across multiple sectors including human
health, animal health and environmental.
The Company is divided into three
business segments:
|
Clinical
|
Broad portfolio of human clinical in vitro diagnostic products,
workflows and services focused on three therapeutic
areas:
·
Reproductive Health: NIPT, Cystic Fibrosis and
other rapid aneuploidy tests
·
Precision Medicine: DPYD genotyping
assay
·
Infectious Diseases: Winterplex, multiplex
winter respiratory PCR panel
|
|
Instrumentation
|
Portfolio of next generation size selection DNA
sample preparation platforms and rapid PCR
machines, including:
·
Ranger® Technology: automated DNA sample
preparation and target enrichment technology
MyGo: real-time quantitative PCR
(qPCR) instruments
|
|
Research Use Only
|
Range of services for the research industry:
· Design,
manufacture, and supply of high-performance qPCR assays and
workflows for use in human health, agriculture, veterinary and
environmental, to support global health organisations and the
research industry
·
Pharmaceutical research services: whole genome sequencing (WGS) /
whole exome sequencing (WES)
|
Novacyt is headquartered in Vélizy
in France with offices in the UK (in Stokesley, Eastleigh and
Manchester), Taipei, Singapore, the US and Canada and has a
commercial presence in over 65 countries. The Company is listed on
the London Stock Exchange's AIM market ("NCYT") and on the Paris
Stock Exchange Euronext Growth ("ALNOV").
For more information, please refer
to the website: www.novacyt.com
